I think suppression tactics will be moot after approval. My feelings are once approval is granted, many with money on the sidelines will jump in. The drug industry may attack the MHRA for shifting the guidelines, but approval is approval. The genie will be out of the bottle and absolutely no reason to sell at that point. A lot of talk about shorts covering and I never agreed with it after a point. Almost 2 years now they have had opportunity to cover, but we see minor SP fluctuations of a penny here and a penny there. NWBO has to make good on its promise to flood the market with PRs though. The PRs should be drafted by this point hammering home a new proven treatment for cancer. MHRA should also PR a reason for such a long wait, leaving no doubt dc-vax is the real deal.
Upon approval, worst case scenario is mngmt takes opportunity on SP rise to dilute substantially for much needed money. Understandable, but I hope they keep the eventual upward momentum going.
Right now I feel SP downward movement is due to dilution and frustration, not manipulation. Market doing fantastic and many parking money elsewhere. JMO even though I am probably stating the obvious.
Market Data 
Markets 
AI
